Willow Biosciences Inc - Notable progress towards commercialisation
2021 has been a year of notable accomplishments for Willow Biosciences (WLLW). In March, it completed its first commercial-scale production of cannabigerol (CBG). In September, it announced the development of a process for producing high yield cannabigerolic acid (CBGA); both CBG and CBGA are believed to provide health and wellness benefits. WLLW’s processes have the potential to deliver rare cannabinoids at high yields and could give it access to the sizeable cosmetic, consumer and pharmaceutical industries. To expand its valuation, WLLW must continue towards monetising its intellectual property (IP) and further demonstrate that its products can be efficiently scaled to commercial quantities.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.